Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC201 TIL in advanced gynecologic tumors
NCT05098171Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC201 + TIL in gynecologic neoplasms, sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 6 months, Objective Response Rate at 36 months and 4 more. Started Sep 2021; status: recruiting.
02
Drugs
GC201 + TIL
03
Conditions
gynecologic neoplasms
Beyond the preview
Go deeper on NCT05098171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098171.